Pfizer said to be adding $5B to AZ bid

Share this article:

Pfizer has sweetened the pot in its bid for AstraZeneca, Bloomberg reports. The new deal could reach $106 billion, according to a source the news service says is close to the matter.

An offer last week hovered in the $101-billion range, according to recent reports.

If the deal goes through, it would give Pfizer a lower tax rate and grant it access to a number of investigational cancer drugs.

Ian Read met with British lawmakers on April 29 to discuss the bid, according to another Bloomberg source, and the CEO “emphasized the American company's plans to carry out research, development and manufacturing in the UK, as well as the appeal of the British tax system.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.